ARROWHEAD PHARMACEUTICALS, INC. Payments to Acquire Investments
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Payments to Acquire Investments of $136.93 million for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-02-05
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2025-12-31 was $136.93M, a 305.74% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2025-09-30 was $21.64M, a 92.60% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2025-06-30 was $96.72M, a 18.47% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2025-03-31 was $644.14M, a 107.80% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2025 was $796.26M, a 10.45% increase from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2024 was $720.95M, a 192.90% increase from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2023 was $246.14M, a 10.18% increase from fiscal 2022.
- ARROWHEAD PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2022 was $223.39M, a 7.19% decline from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month | Payments to Acquire Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $136.93M 10-Q · filed 2026-02-05 | $158.57M derived: sum of 2 quarters · filed 2026-02-05 | $255.30M derived: sum of 3 quarters · filed 2026-02-05 | $899.44M derived: sum of 4 quarters · filed 2026-02-05 | |
| 2025-09-30 | $21.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $118.37M derived: sum of 2 quarters · filed 2025-11-25 | $762.51M derived: sum of 3 quarters · filed 2025-11-25 | $796.26M 10-K · filed 2025-11-25 | |
| 2025-06-30 | $96.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-07 | $740.87M derived: sum of 2 quarters · filed 2025-08-07 | $774.62M 10-Q · filed 2025-08-07 | $1.07B derived: sum of 4 quarters · filed 2026-02-05 | |
| 2025-03-31 | $644.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-12 | $677.89M 10-Q · filed 2025-05-12 | $970.23M derived: sum of 3 quarters · filed 2026-02-05 | $1.09B derived: sum of 4 quarters · filed 2026-02-05 | |
| 2024-12-31 | $33.75M 10-Q · filed 2026-02-05 | $326.08M derived: sum of 2 quarters · filed 2026-02-05 | $444.71M derived: sum of 3 quarters · filed 2026-02-05 | $754.70M derived: sum of 4 quarters · filed 2026-02-05 | |
| 2024-09-30 | $292.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $410.96M derived: sum of 2 quarters · filed 2025-11-25 | $720.95M derived: sum of 3 quarters · filed 2025-11-25 | $720.95M 10-K · filed 2025-11-25 | |
| 2024-06-30 | $118.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-07 | $428.61M derived: sum of 2 quarters · filed 2025-08-07 | $428.61M 10-Q · filed 2025-08-07 | $440.77M derived: sum of 4 quarters · filed 2025-11-25 | |
| 2024-03-31 | $309.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-12 | $309.98M 10-Q · filed 2025-05-12 | $322.14M derived: sum of 3 quarters · filed 2025-11-25 | $363.60M derived: sum of 4 quarters · filed 2025-11-25 | |
| 2023-12-31 | $0.00 10-Q · filed 2025-02-10 | $12.16M derived: sum of 2 quarters · filed 2025-11-25 | $53.61M derived: sum of 3 quarters · filed 2025-11-25 | $134.94M derived: sum of 4 quarters · filed 2025-11-25 | |
| 2023-09-30 | $12.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $53.61M derived: sum of 2 quarters · filed 2025-11-25 | $134.94M derived: sum of 3 quarters · filed 2025-11-25 | $246.14M 10-K · filed 2025-11-25 | |
| 2023-06-30 | $41.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-08 | $122.78M derived: sum of 2 quarters · filed 2024-08-08 | $233.98M 10-Q · filed 2024-08-08 | $233.98M derived: sum of 4 quarters · filed 2024-11-26 | |
| 2023-03-31 | $81.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09 | $192.53M 10-Q · filed 2024-05-09 | $192.53M derived: sum of 3 quarters · filed 2024-11-26 | $267.53M derived: sum of 4 quarters · filed 2024-11-26 | |
| 2022-12-31 | $111.20M 10-Q · filed 2024-02-06 | $111.20M derived: sum of 2 quarters · filed 2024-11-26 | $186.20M derived: sum of 3 quarters · filed 2024-11-26 | $268.71M derived: sum of 4 quarters · filed 2024-11-26 | |
| 2022-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $75.00M derived: sum of 2 quarters · filed 2024-11-26 | $157.52M derived: sum of 3 quarters · filed 2024-11-26 | $223.39M 10-K · filed 2024-11-26 | |
| 2022-06-30 | $75.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | $157.52M derived: sum of 2 quarters · filed 2023-08-07 | $223.39M 10-Q · filed 2023-08-07 | $368.90M derived: sum of 4 quarters · filed 2023-11-29 | |
| 2022-03-31 | $82.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-02 | $148.39M 10-Q · filed 2023-05-02 | $293.90M derived: sum of 3 quarters · filed 2023-11-29 | $349.09M derived: sum of 4 quarters · filed 2023-11-29 | |
| 2021-12-31 | $65.88M 10-Q · filed 2023-02-06 | $211.38M derived: sum of 2 quarters · filed 2023-11-29 | $266.58M derived: sum of 3 quarters · filed 2023-11-29 | ||
| 2021-09-30 | $145.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $200.70M derived: sum of 2 quarters · filed 2023-11-29 | $240.70M 10-K · filed 2023-11-29 | ||
| 2021-06-30 | $55.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-04 | $95.19M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $40.00M 10-Q · filed 2022-05-10 | ||||
| 2020-09-30 | $85.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | $98.44M derived: sum of 2 quarters · filed 2022-11-28 | $278.96M 10-K · filed 2022-11-28 | $278.96M 10-K · filed 2020-11-23 | |
| 2020-06-30 | $13.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-05 | $193.96M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $180.52M 10-Q · filed 2021-05-04 | ||||
| 2019-09-30 | $90.27M 10-K · filed 2021-11-22 | $90.27M 10-K · filed 2020-11-23 | |||
| 2018-09-30 | $52.08M 10-K · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |